ClinicalTrials.gg
CompletedNCT00323297Updated Feb 1, 2021Results posted

Assess the Efficacy and Safety of Sildenafil When Added to Bosentan in the Treatment of Pulmonary Arterial Hypertension

A Phase 4 interventional study of Bosentan and Placebo in Pulmonary Arterial Hypertension, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc.. Completed at 30 sites in 10 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-02-01.

Sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (part of Viatris Inc.) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
105
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 18 studies testing sildenafil in Pulmonary Arterial Hypertension — 1 open to participants now, 1 under way, 1 of them phase 3. sildenafil · Pulmonary Arterial Hypertension.

Enrollment
5th of 18
105 · median 23
Started
2006
with 1 other
Phase 4
6 of 18
none open now
Registered
5th of 18
by date
Lead sponsor
7 of 18
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Among the 18 studies testing sildenafil in Pulmonary Arterial Hypertension, this one is the 5th largest by enrollment, is one of 2 that started in 2006, is one of 6 in phase 4, and was the 5th registered.

Pulmonary Arterial Hypertension

700 studies on the registry are indexed under Pulmonary Arterial Hypertension; 140 are open to participants now.

Browse Pulmonary Arterial Hypertension studies →

Open to participants now

1 of the 18 studies testing sildenafil in Pulmonary Arterial Hypertension is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About sildenafil

sildenafil: first FDA approval 1998 (VIAGRA), first EMA approval 1998. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 90 Pulmonary Arterial Hypertension studies recruiting now, 51 (57%) set no upper age limit and 24 (27%) stop at 75 or younger; 18 take children under 18; 11 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies testing sildenafil in Pulmonary Arterial Hypertension, or all of them as a file.
02

Study summary

To assess the efficacy and safety of sildenafil when added to patients with PAH who are taking bosentan as all or part of their background therapy.

03

Conditions studied

  • Pulmonary Arterial Hypertension
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects aged 18 and over above with PAH and for which bosentan therapy is indicated according to national license
  • Subjects with a mean pulmonary artery pressure of >25mmHg and a pulmonary artery wedge pressure of \<15mmHg at rest via right heart catheterization within 3 years prior to randomization.
  • Subjects whose baseline 6 Minute Walk Test distance is >100m and \< 450m.

Exclusion criteria

Exclusion Criteria:

  • PAH secondary to any aetiology including congenital heart disease other than those specified in the inclusion criteria
  • Subjects whose 6 Minute Walk Test may be limited by conditions other than PAH related dyspnoea or fatigue eg. claudication from vascular insufficiency or arthritis.
05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
105 participants (actual)

Study arms

  • Placebo comparator
    placebo

    Drug: Bosentan · Other: Placebo

  • Experimental
    Active

    Drug: Bosentan · Drug: Sildenafil Citrate

Interventions

  • Bosentan + Placebo for 12 weeks of the study (double blind), then 12 months open label phase (bosentan + sildenafil)

  • OtherPlacebo

    Bosentan + Placebo for 12 weeks of the study (double blind), then 12 months open label phase (bosentan + sildenafil)

  • Bosentan + Sildenafil for 12 weeks of the study (double blind), then 12 months open label phase

  • Bosentan + Sildenafil for 12 weeks of the study (double blind), then 12 months open label phase

06

What researchers measure

Primary outcomes

  1. Change From Baseline in the Total Distance Walked During 6 Minute Walk Time (6MWT) at Week 12

    6MWT is the distance that a participant could walk in 6 minutes. Participants were asked to perform the test at a pace that was comfortable to them, with as many breaks as they needed. Continuous pulse oximetry was conducted during the test for safety.

    Time frame: Week 12

Secondary outcomes

  1. Number of Participants With Change From Baseline in World Health Organization (WHO) Functional Class in Participants With PAH at Week 12 LOCF

    WHO functional classification for PAH range from Class I (no limitation in physical activity, no dyspnea with normal activity) to Class IV (can not perform a physical activity without any symptoms, dyspnea at rest). Improvement=reduction in functional class; deterioration = increase in functional class, no change = no change in functional class.

    Time frame: Week 12

  2. Clinical Worsening Events

    No survival analysis was carried out for the study due to very few events of clinical worsening. Hence, we present a summary of clinical worsening events instead. Events of clinical worsening were categorized as (A). Death, (B). Heart/lung transplantation, (C). Hospitalization due to pulmonary arterial hypertension (PAH), and (D). Clinical deterioration of PAH requiring additional therapy.

    Time frame: Week 12

  3. Change From Baseline in Borg Dyspnea Score at Week 12

    Borg dyspnea scale is a 10-point scale where following scores stands for severity of dyspnea: 0 (no breathlessness at all); 0.5 (very very slight \[just noticeable\]); 1. (very slight); 2. (slight breathlessness); 3. (moderate); 4 (some what severe); 5 (severe breathlessness); 7 (very severe breathlessness); 9 (very very severe \[almost maximum\]); and 10 (maximum).

    Time frame: Week 12

  4. One Year Survival Probability From the Start of Sildenafil Treatment.

    The survival probability of all participants up to 1-year post start of Sildenafil treatment; for participants who were randomized to Sildenafil, this was the week 52 from randomization, and for participants who were originally randomized to Placebo group, this was the Week 64 from Baseline (Week 52 from Week 12, when the first dose of Sildenafil was administered to these participants). Those participants who discontinued from the study prior to 1 year after start of sildenafil were considered as censored at the time of discontinuation and those who discontinued from the study post 1-year after start of sildenafil were considered as censored at the time of 1-year post start of sildenafil.

    Time frame: One year from the time of starting sildenafil

  5. One Year Survival From the Start of Sildenafil Treatment.

    The survival status of all participants who discontinued from the study, including those participants who discontinued during the double-blind phase, was to be assessed at one year post their Week 12 visit/ End of treatment visit.

    Time frame: One year from the time of starting sildenafil

07

Results

Posted Nov 19, 2013

Participant flow

This study was conducted at 29 active centers in 10 countries (10 centers in Germany, 5 centers in the United States of America \[USA\], 3 centers in France, 2 centers in Australia, Czech Republic, Italy, and Israel, and 1 center in Greece, Taiwan and United Kingdom \[UK\])

Part A (Double Blind Randomized)
Participant flow — Part A (Double Blind Randomized)
MilestonePlaceboSildenafil
Started5350
Completed4843
Not completed57
Withdrew: Reason unspecified01
Withdrew: Death01
Withdrew: Protocol violation13
Withdrew: Unrelated adverse event10
Withdrew: Related and unrelated adverse event10
Withdrew: Related adverse event22
Part B (Open-label)
Participant flow — Part B (Open-label)
MilestonePlaceboSildenafil
Started4843
Completed3931
Not completed912
Withdrew: Death01
Withdrew: Reason unspecified01
Withdrew: Withdrawal by subject13
Withdrew: Lack of efficacy31
Withdrew: Adverse event55
Withdrew: Protocol violation01

Outcome measures

PrimaryChange From Baseline in the Total Distance Walked During 6 Minute Walk Time (6MWT) at Week 12

6MWT is the distance that a participant could walk in 6 minutes. Participants were asked to perform the test at a pace that was comfortable to them, with as many breaks as they needed. Continuous pulse oximetry was conducted during the test for safety.

Time frame:
Week 12
Reported as:
Mean · Meters
Change From Baseline in the Total Distance Walked During 6 Minute Walk Time (6MWT) at Week 12
MetersPlaceboSildenafil
Change from baseline at Week 12 (n=46,44)17.42 ± 57.27014.08 ± 63.679
Change from baseline at Week 12 LOCF (n=53,49)14.08 ± 57.55713.62 ± 60.950
Statistical analysis
  • Placebo vs Sildenafil · ANCOVA · p = 0.5802 (A sequential closed-testing procedure was implemented for all secondary endpoints. If no statistically significant treatment effect was found for the primary endpoint then statistical tests were not to be performed on the secondary endpoints.) · Mean difference (final values): -2.38 · 90% CI -21.843 to 17.087The mean difference in method of estimation is the difference between Sildenafil - placebo.
SecondaryNumber of Participants With Change From Baseline in World Health Organization (WHO) Functional Class in Participants With PAH at Week 12 LOCF

WHO functional classification for PAH range from Class I (no limitation in physical activity, no dyspnea with normal activity) to Class IV (can not perform a physical activity without any symptoms, dyspnea at rest). Improvement=reduction in functional class; deterioration = increase in functional class, no change = no change in functional class.

Time frame:
Week 12
Reported as:
Number · Participants
Number of Participants With Change From Baseline in World Health Organization (WHO) Functional Class in Participants With PAH at Week 12 LOCF
ParticipantsPlaceboSildenafil
Worsened 2 Classes00
Worsened 1 Class10
No Change4539
Improved 1 Class710
Improved 2 Classes00
Discontinued00
Died01
Missing00
SecondaryClinical Worsening Events

No survival analysis was carried out for the study due to very few events of clinical worsening. Hence, we present a summary of clinical worsening events instead. Events of clinical worsening were categorized as (A). Death, (B). Heart/lung transplantation, (C). Hospitalization due to pulmonary arterial hypertension (PAH), and (D). Clinical deterioration of PAH requiring additional therapy.

Time frame:
Week 12
Reported as:
Number · Participants
Clinical Worsening Events
ParticipantsPlaceboSildenafil
None5147
(A)01
(B)00
(C)22
(D)00
SecondaryChange From Baseline in Borg Dyspnea Score at Week 12

Borg dyspnea scale is a 10-point scale where following scores stands for severity of dyspnea: 0 (no breathlessness at all); 0.5 (very very slight \[just noticeable\]); 1. (very slight); 2. (slight breathlessness); 3. (moderate); 4 (some what severe); 5 (severe breathlessness); 7 (very severe breathlessness); 9 (very very severe \[almost maximum\]); and 10 (maximum).

Time frame:
Week 12
Reported as:
Mean · Units on a scale
Change From Baseline in Borg Dyspnea Score at Week 12
Units on a scalePlaceboSildenafil
Change from Baseline at Week 12 (n=46,43)0.16 ± 1.637-0.73 ± 1.656
Change from Baseline at Week 12 LOCF (n=53,49)0.24 ± 1.709-0.62 ± 1.583
SecondaryOne Year Survival Probability From the Start of Sildenafil Treatment.

The survival probability of all participants up to 1-year post start of Sildenafil treatment; for participants who were randomized to Sildenafil, this was the week 52 from randomization, and for participants who were originally randomized to Placebo group, this was the Week 64 from Baseline (Week 52 from Week 12, when the first dose of Sildenafil was administered to these participants). Those participants who discontinued from the study prior to 1 year after start of sildenafil were considered as censored at the time of discontinuation and those who discontinued from the study post 1-year after start of sildenafil were considered as censored at the time of 1-year post start of sildenafil.

Time frame:
One year from the time of starting sildenafil
Reported as:
Number · Probability of death
One Year Survival Probability From the Start of Sildenafil Treatment.
Probability of deathPlaceboSildenafil
One Year Survival Probability From the Start of Sildenafil Treatment.0.042 (0.013 to 0.127)0.040 (0.013 to 0.124)
SecondaryOne Year Survival From the Start of Sildenafil Treatment.

The survival status of all participants who discontinued from the study, including those participants who discontinued during the double-blind phase, was to be assessed at one year post their Week 12 visit/ End of treatment visit.

Time frame:
One year from the time of starting sildenafil
Reported as:
Number · Participants who died
One Year Survival From the Start of Sildenafil Treatment.
Participants who diedPlaceboSildenafil
One Year Survival From the Start of Sildenafil Treatment.22

Adverse events

Collected over From the time that the participant provides informed consent through and including 28 calendar days after the last administration of the investigational product. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo—23/53 (43.4%)38/53 (71.7%)
Sildenafil—22/50 (44%)33/50 (66%)
Most frequent serious events
Showing 10 of 55
Most frequent serious events
EventPlaceboSildenafil
Pulmonary arterial hypertensionRespiratory, thoracic and mediastinal disorders6/532/50
Right ventricular failureCardiac disorders1/533/50
BronchopneumoniaInfections and infestations1/532/50
DyspnoeaRespiratory, thoracic and mediastinal disorders2/532/50
AnaemiaBlood and lymphatic system disorders2/531/50
Abdominal painGastrointestinal disorders2/530/50
ErysipelasInfections and infestations2/530/50
Pleural effusionRespiratory, thoracic and mediastinal disorders2/530/50
PneumoniaInfections and infestations2/530/50
Acute coronary syndromeCardiac disorders0/531/50
Most frequent other events
Showing 10 of 29
Most frequent other events
EventPlaceboSildenafil
Oedema peripheralGeneral disorders8/537/50
NasopharyngitisInfections and infestations8/535/50
DyspnoeaRespiratory, thoracic and mediastinal disorders8/533/50
DiarrhoeaGastrointestinal disorders5/537/50
HeadacheNervous system disorders7/537/50
VertigoEar and labyrinth disorders2/535/50
BronchitisInfections and infestations5/535/50
FlushingVascular disorders4/535/50
PalpitationsCardiac disorders3/535/50
NauseaGastrointestinal disorders5/531/50

Baseline characteristics

Age, Continuous
Age, Continuous(Years)PlaceboSildenafilTotal
Mean56.9 ± 14.1455.2 ± 15.1056.0 ± 14.57
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboSildenafilTotal
Female413778
Male121325
Six Minute Walk Test (6MWT)
Six Minute Walk Test (6MWT)(Meters)PlaceboSildenafilTotal
Mean350.38 ± 87.587354.44 ± 73.121352.35 ± 80.520
Mean Pulmonary Artery Pressure (mPAP)
Mean Pulmonary Artery Pressure (mPAP)(Millimeter(mm) of mercury(Hg))PlaceboSildenafilTotal
Mean44.9 ± 13.3346.9 ± 12.4745.8 ± 12.89
World Health Organization Functional Class in Participants with Pulmonary Arterial Hypertension
World Health Organization Functional Class in Participants with Pulmonary Arterial Hypertension(Participants)PlaceboSildenafilTotal
Class I000
Class II152035
Class III382967
Class IV011
08

Study locations

30 sites
  • West Los Angeles VA Healthcare, Pulmonary Hypertension Program
    Los Angeles, California 90073, United States
  • Henry Ford Hospital
    Detroit, Michigan 48202, United States
  • Allegheny General Hospital
    Pittsburgh, Pennsylvania 15212, United States
  • Baylor College of Medicine
    Houston, Texas 77030, United States
  • The Methodist Hospital
    Houston, Texas 77030, United States
  • Diagnostics Research Group
    San Antonio, Texas 78229, United States
  • St. Vincents Hospital
    Darlinghurst, New South Wales 2010, Australia
  • The Prince Charles Hospital
    Chermside, Queensland 4032, Australia
  • Vseobecna fakultni nemocnice v Praze
    Praha 2, 128 08, Czechia
  • Institut klinicke a experimentalni mediciny, Klinika kardiologie
    Praha 4, 140 21, Czechia
  • Clinique des Maladies Respiratoires
    Lille, 59037, France
  • Hopital Claude Huriez
    Lille, 59037, France
  • Hopital Adules Brabois
    Vandoeuvre Les Nancy, 54511, France
  • Unfallkrankenhaus Berlin, Klinik fuer Innere Medizin
    Berlin, 12683, Germany
  • II. Medizinische Klinik, Kardiologie, Angiologie und Pneumologie
    Coburg, 96450, Germany
  • Universitaetsklinikum Essen, Zentrum fuer Innere Medizin, Klinik fuer Kardiologie
    Essen, 45122, Germany
  • Universitaetsklinikum Giessen und Marburg GmbH, Standort Giessen
    Giessen, 35392, Germany
  • Medizinische Hochschule Hannover
    Hannover, 30625, Germany
  • Universitaetsklinikum des Saarlandes, Innere Medizin V
    Homburg, 66421, Germany
  • Medizinische Klinik und Poliklinik I, Universitaetsklinikum Leipzig
    Leipzig, 04103, Germany
  • Med. Klinik u. Poliklinik I der LMU Muenchen, Klinikum Grosshadern
    Muenchen, 81377, Germany
  • Praxis fuer Innere Medizin, Kardiologie und Angiologie
    Nuernberg, 90402, Germany
  • Missionsaerztliche Klinik Wuerzburg, Gemeinnuetzige Gesellschaft mbH
    Wuerzburg, 97067, Germany
  • Attikon Hospital
    Haidari, Athens 12462, Greece
  • Rambam Medical Center
    Haifa, 31096, Israel
  • Rabin Medical Centre
    Petach Tikva, 49100, Israel
  • Cardiologia, Azienda Ospedaliera Monaldi, Seconda Università di Napoli
    Napoli, 80131, Italy
  • Unita' di Ipertensione Polmonare, Dipartimento di Scienze Respiratorie e Cardiovascolari
    Roma, 00161, Italy
  • Department of Surgery, National Taiwan University Hospital
    Taipei, 100, Taiwan
  • PVDU
    Papworth Everard, Cambridgeshire CB23 3RE, United Kingdom
09

References and documents

Publications

  • Vizza CD, Jansa P, Teal S, Dombi T, Zhou D. Sildenafil dosed concomitantly with bosentan for adult pulmonary arterial hypertension in a randomized controlled trial. BMC Cardiovasc Disord. 2017 Sep 6;17(1):239. doi: 10.1186/s12872-017-0674-3. PubMed 28874133 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2006, a primary completion of Aug 2013 and a completion of Aug 2013. It does not say whether these dates are actual or estimated.

Results were first posted in Nov 2013, 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
May 5, 2006
First posted
May 9, 2006
Start
Sep 2006
Primary completionActual
Aug 2013
CompletionActual
Aug 2013
Results first posted
Nov 19, 2013
Last update
Feb 1, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 1, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00323297
Responsible party
Sponsor
First posted
May 9, 2006
Start date
Sep 2006
Primary completion
Aug 2013
Completion
Aug 2013
Results posted
Nov 19, 2013
Last update
Feb 1, 2021

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sildenafil

Start the discussion